TEAS RF New Application

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88177424

Filing Date: 11/01/2018

To the Commissioner for Trademarks:

MARK: INNOVENT (stylized and/or with design, see mark)

The literal element of the mark consists of INNOVENT.
The mark consists of the word INNOVENT; the "O" in "INNOVENT" is comprised of two symmetrical arcs, with Chinese characters beneath the word INNOVENT.
The applicant, Innovent Biologics (Suzhou) Co., Ltd., a limited company (ltd.) legally organized under the laws of China, having an address of
      Suzhou Industrial Park
      No. 168 Dongping Street
      Suzhou City 215123
      China

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

       International Class 005:  Medicines for human purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; drugs for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; chemico-pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; chemical preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; injectable preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; biological preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; vaccines; diagnostic preparations for medical purposes; dietetic substances adapted for medical use; biological preparations extracted from blood for medical use; biological tissue cultures for medical purposes; nutraceutical preparations for therapeutic or medical purposes
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The applicant's current Attorney Information:
      Anessa Owen Kramer and Julie E. Reitz, Angela Alvarez Sujek, Jennifer M. Hetu, Nicole M. Kryzhan, Amanda M. Blackburn of Honigman Miller Schwartz and Cohn LLP      39400 Woodward Avenue, Suite 101
      Bloomfield Hills, Michigan 48304-5151
      United States
      trademark@honigman.com (authorized)

The applicant's current Correspondence Information:

Anessa Owen Kramer

Honigman Miller Schwartz and Cohn LLP

39400 Woodward Avenue, Suite 101

Bloomfield Hills, Michigan 48304-5151

trademark@honigman.com (authorized) E-mail Authorization: I authorize the USPTO to send e-mail correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the e-mail address provided in this application. I understand that a valid e-mail address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of $125 per international class of goods/services.

A fee payment in the amount of $275 has been submitted with the application, representing payment for 1 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /anessa kramer/   Date: 10/31/2018
Signatory's Name: Anessa Owen Kramer
Signatory's Position: Attorney of Record, Michigan Bar Member
Payment Sale Number: 88177424
Payment Accounting Date: 11/01/2018

Serial Number: 88177424
Internet Transmission Date: Thu Nov 01 07:40:50 EDT 2018
TEAS Stamp: USPTO/BAS-XX.XX.XX.XX-201811010740504175
70-88177424-610f84f5bd3caee574fba1495a46
d775a2f164e8f9838f72deef299c23cfa213b5-D
A-9674-20181031154259587415